Sera Prognostics Stock (NASDAQ:SERA)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$3.07

52W Range

$1.37 - $9.13

50D Avg

$2.78

200D Avg

$4.03

Market Cap

$113.88M

Avg Vol (3M)

$308.76K

Beta

1.00

Div Yield

SERA Company Profile

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jul 15, 2021

Website

SERA Performance

SERA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$77.00K	$306.00K	$268.00K
Operating Income	$-36.63M	$-39.82M	$-45.65M
Net Income	$-32.90M	$-36.24M	$-44.25M
EBITDA	$-36.63M	$-35.29M	$-42.91M
Basic EPS	$-0.99	$-1.16	$-1.43
Diluted EPS	$-0.99	$-1.16	$-1.43

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 07, 25 | 5:00 PM

Q1 25May 11, 25 | 5:00 PM

Q4 24Mar 19, 25 | 5:00 PM

Peer Comparison

Ticker	Company
TCRX	TScan Therapeutics, Inc.
RNAZ	TransCode Therapeutics, Inc.
RPID	Rapid Micro Biosystems, Inc.
XGN	Exagen Inc.
CSTL	Castle Biosciences, Inc.
FONR	FONAR Corporation
ELEV	Elevation Oncology, Inc.
UNCY	Unicycive Therapeutics, Inc.